Associated Papers
Leveraging oncology clinical case report data through the Cancer Knowledgebase (CKB).
Gokhale RH et al.
Personalized Medicine, 2025
Molecular Basis of BRAF Inhibitor Resistance in Melanoma: A Systematic Review.
Cosci I et al.
Pharmaceuticals (basel, Switzerland), 2025
GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway.
Ikeuchi H et al.
Oncogene, 2024
Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World Setting.
Vanni I et al.
International Journal of Molecular Sciences, 2023
Molecular characterization of adenocarcinomas arising in the urinary bladder following augmentation cystoplasty: a multi-institutional study.
Stohr BA et al.
Human Pathology, 2022
BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies.
Zhong J et al.
Current Treatment Options in Oncology, 2022
Cholesterol Regulates the Tumor Adaptive Resistance to MAPK Pathway Inhibition.
Wang XD et al.
Journal of Proteome Research, 2021
NGS Analysis of Liquid Biopsy (LB) and Formalin-Fixed Paraffin-Embedded (FFPE) Melanoma Samples Using Oncomine™ Pan-Cancer Cell-Free Assay.
Olbryt M et al.
Genes, 2021
MEK inhibitors for the treatment of non-small cell lung cancer.
Han J et al.
Journal of Hematology & Oncology, 2021
New genetic variations discovered in KRAS wild-type cetuximab resistant chinese colorectal cancer patients.
Jing C et al.
Molecular Carcinogenesis, 2020
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.
Hamid AB et al.
Cancers, 2020
Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity.
Hartman ML et al.
Cells, 2020
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
Punta M et al.
Frontiers in Immunology, 2020
V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer.
Gao Y et al.
Cancer Discovery, 2019
Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia.
Giménez N et al.
Haematologica, 2019
Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance.
Vikova V et al.
Theranostics, 2019
Intrinsically active MEK variants are differentially regulated by proteinases and phosphatases.
Ordan M et al.
Scientific Reports, 2018
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.
Emery CM et al.
Molecular Cancer Research : Mcr, 2017
Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy.
Mandal R et al.
Oncogene, 2016
Gain-of-Function Mutations in the Toll-Like Receptor Pathway: TPL2-Mediated ERK1/ERK2 MAPK Activation, a Path to Tumorigenesis in Lymphoid Neoplasms?
Rousseau S et al.
Frontiers in Cell and Developmental Biology, 2016
Targeting the RAS pathway by mitogen-activated protein kinase inhibitors.
Kiessling MK et al.
Swiss Medical Weekly, 2015
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.
Long GV et al.
Nature Communications, 2014
Structure-energy-based predictions and network modelling of RASopathy and cancer missense mutations.
Kiel C et al.
Molecular Systems Biology, 2014
MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
Wagle N et al.
Cancer Discovery, 2014
Towards a unified model of RAF inhibitor resistance.
Solit DB et al.
Cancer Discovery, 2014
The FBXO4 tumor suppressor functions as a barrier to BRAFV600E-dependent metastatic melanoma.
Lee EK et al.
Molecular and Cellular Biology, 2013
Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.
Villanueva J et al.
Cell Reports, 2013
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).
Nathanson KL et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2013
Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.
Greger JG et al.
Molecular Cancer Therapeutics, 2012